Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the “Public Offering”) of 5,649,122 common shares of the Company (the “Common Shares”) and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose Biosciences (NASDAQ: APTO ) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company's shares. Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share.

Why Is Aptose Biosciences (APTO) Stock Down Today?

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the pricing of an underwritten public offering (the “Public Offering”) of 4,912,280 common shares of the Company (the “Common Shares”) at a public offering price of US $1.71 per share. Each Common Share will also include a warrant to purchase a Common Share (a “Warrant Share”) at a price of $1.71 per Warrant Share.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination Active Across Broad Populations of AML and Demonstrates 25% Complete Response Rate Among All-comers, including 20% CRc in Wildtype AML TUS Targets VEN Resistance Mechanisms, Enabling TUS/VEN Combination to Achieve Responses in Difficult-to-treat Prior-VEN Failure AML Total Enrollment of Patients Receiving TUS or TUS/VEN is Now Over 160 SAN DIEGO and TORONTO, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that a growing body of clinical data for Aptose's lead compound tuspetinib (TUS), demonstrates significant benefit as a single agent and in combination with venetoclax (VEN) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) in the ongoing APTIVATE Phase 1/2 study. Data were presented in an oral presentation today at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by lead investigator Naval G.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr.

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today.

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path

Aptose Reports Results for the Third Quarter 2023

SAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that clinical data for tuspetinib, a once daily oral therapy, has been selected for oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA. Lead investigator Naval Daver, MD, Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, will present data from Aptose's ongoing APTIVATE trial of tuspetinib in relapsed/refractory patients with acute myeloid leukemia.

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted   TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure R/R AML Patients 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients Consistent Favorable Safety with TUS Single Agent and TUS/VEN Doublet SAN DIEGO and TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, released highlights from a clinical update event held today, October 30, 2023, in conjunction with the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held in Estoril, Portugal (the “ESH 2023 Conference”). The webcast event featured a comprehensive review of up-to-date clinical data for Aptose's lead compound tuspetinib (TUS) by Rafael Bejar, MD, PhD, Aptose's Chief Medical Officer, and featured Naval G.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast:       Date: Thursday, November 9, 2023  Time:  5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link (https://register.vevent.com/register/BIb770b610b0744016870ec2150989ea78)   *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call.

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Company will provide a clinical update on Monday, October 30, 2023 at 8:30 AM Eastern Time, in conjunction with poster presentations at the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, being held October 29-31, 2023, in Estoril, Portugal. The webcast event will include a comprehensive review of up-to-date clinical data for Aptose's lead compound tuspetinib and will feature Naval Daver, MD, Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.

Aptose to Present at the Cantor Global Healthcare Conference

— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, in New York City.

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy - JonesTrading Anish Nikhanj - RBC Capital Markets Operator Good afternoon. My name is Zeda and I will be your conference operator today.

Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript

─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─

Aptose Reports Results for the Second Quarter 2023

SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the market, and provide a corporate update.

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it meets compliance with the Nasdaq's minimum bid price requirement.

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML Patients Favorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML Populations TP53 MUT CR/CRh = 20% │ RAS MUT CR/CRh = 22%

Aptose Presents Highlights from Clinical Update

SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the Company effected a reverse stock split on May 24, 2023 at a ratio of 15-to-1 (the “Reverse Stock Split”). Both the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) have approved the Reverse Stock Split and have informed the Company that its common shares (the “Common Shares”) will commence trading on a post-Reverse Stock Split basis at market open on Tuesday, June 6, 2023.

Aptose Biosciences Provides Update on Reverse Stock Split

SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the company management team will provide a clinical update on Saturday, June 10, 2023, at 12:00 PM EST / 6:00 PM CEST, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany. The webcast event will include an interim review of Aptose's lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial.

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

Aptose Enters into $25 Million Committed Equity Facility

SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that, at the Company's annual and special meeting of shareholders held today, May 23, 2023 (the “Meeting”), the proposed reverse stock split (the “Reverse Stock Split”) of the Company's common shares (the “Common Shares”), as described in the proxy statement dated April 18, 2023 (the “Proxy Statement”), was approved by 93.44% of the votes cast at the Meeting. The Company also announced today that the board of directors of the Company approved the implementation of the Reverse Stock Split immediately after the Meeting on the basis of 15 pre-Reverse Stock Split Common Shares for each one post-Reverse Stock Split Common Share.

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

Achilles Therapeutics PLC

Checkpoint Therapeutics

If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.

News for Aptose Biosciences Stock (APTO)